News Quantified

LPTX – leap therapeutics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Leap Therapeutics, Inc. (NASDAQ: LPTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.50 price target on the stock.

Leap Therapeutics Reports Third Quarter 2024 Financial Results

Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

-7.1%

BEAT

-4.8%

MISS

-2.7%

BEAT

Form 4 LEAP THERAPEUTICS, INC. For: Nov 13 Filed by: CAVANAUGH JAMES H

Form 4 LEAP THERAPEUTICS, INC. For: Nov 13 Filed by: ONSI DOUGLAS E

Form 4 LEAP THERAPEUTICS, INC. For: Nov 13 Filed by: LAWLOR AUGUSTINE

Form 4 LEAP THERAPEUTICS, INC. For: Nov 13 Filed by: Mirabelli Christopher

Form SC 13G LEAP THERAPEUTICS, INC. Filed by: BALYASNY ASSET MANAGEMENT L.P.

Top News Gainers

1/3 Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity Financing 51.9%

1/4 Leap Therapeutics Inc (NASDAQ: LPTX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.25 price target on the stock. 20.6%

2/26 Leap Therapeutics to Present at Cowen 40th Annual Health Care Conference 15.0%

3/23 Form 3 LEAP THERAPEUTICS, INC. For: Mar 12 Filed by: BeiGene, Ltd. 14.5%

4/20 Form SC 13G LEAP THERAPEUTICS, INC. Filed by: PERCEPTIVE ADVISORS LLC 13.8%

3/18 Form 8-K LEAP THERAPEUTICS, INC. For: Mar 17 12.8%

4/23 Leap Therapeutics to Present Updated Data for DKN-01 Monotherapy and Paclitaxel Combination In Gynecologic Cancers 12.2%

1/23 Leap Therapeutics Presents Updated Data at the ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI) Global Meeting 11.7%

6/12 Form 4 LEAP THERAPEUTICS, INC. For: Jun 11 Filed by: LAWLOR AUGUSTINE 10.3%

3/17 Leap Therapeutics Inc (NASDAQ: LPTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.50 price target on the stock. 8.4%

Top News Decliners

11/14 Q3/2019 9/30/2019 EPS -0.330 ZacksConsensus -0.330 ActVsEst 0.000 - In-Line -53.6%

8/6 Form 8-K LEAP THERAPEUTICS, INC. For: Aug 06 -23.0%

3/18 Leap Therapeutics Announces Executive Leadership Changes -19.3%

9/17 Form 8-K LEAP THERAPEUTICS, INC. For: Sep 16 -18.3%

3/16 Form 10-K LEAP THERAPEUTICS, INC. For: Dec 31 -12.2%

7/11 Leap Therapeutics Announces Common Stock Purchase Agreements For Up to $21 Million with Lincoln Park Capital -7.9%

2/1 Leap Therapeutics Inc (NASDAQ: LPTX) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -7.6%

3/4 Form 4 LEAP THERAPEUTICS, INC. For: Mar 02 Filed by: LITTLECHILD JOHN W -7.1%

3/9 Form 8-K LEAP THERAPEUTICS, INC. For: Mar 05 -6.4%

6/5 Leap Therapeutics Inc (NASDAQ: LPTX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.6%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day